PDF(Pubmed)
Abstract：
The therapeutic landscape for aHCC has evolved in recent years, necessitating a comprehensive analysis of treatment patterns, clinical outcomes, HCRU, and costs to contextualize emerging treatments. This study aimed to investigate these outcomes using real-world data from Ontario, Canada. This retrospective cohort study was conducted using linked administrative databases from April 2010 to March 2020. Patients diagnosed with aHCC were included, and their clinical and demographic characteristics were analyzed, as well as treatment patterns, survival, HCRU, and economic burden. Among 7322 identified patients, 802 aHCC patients met the eligibility criteria for inclusion in the study. Treatment subgroups included 1L systemic therapy (53.2%), other systemic treatments (4.5%), LRT (9.0%), and no treatment (33.3%). The median age was 66 years, and the majority were male (82%). The mOS for the entire cohort from diagnosis was 6.5 months. However, patients who received 1L systemic therapy had an mOS of 9.0 months, which was significantly higher than the other three subgroups. The mean cost per aHCC-treated patient was $49,640 CAD, with oral medications and inpatient hospitalizations as the largest cost drivers. The results underscore the need for the continuous evaluation and optimization of HCC management strategies in the era of evolving therapeutic options.
摘要：
aHCC的治疗前景近年来有所发展，需要对治疗模式进行全面分析，临床结果，HCCU,以及将新出现的治疗方法情境化的成本。本研究旨在使用安大略省的实际数据调查这些结果，加拿大。这项回顾性队列研究是使用2010年4月至2020年3月的关联管理数据库进行的。包括诊断为aHCC的患者，并分析了他们的临床和人口统计学特征，以及治疗模式，生存,HCCU,和经济负担。在7322名患者中，802例aHCC患者符合纳入研究的资格标准。治疗亚组包括1L全身治疗（53.2%），其他全身治疗（4.5%），轻轨（9.0%），无治疗（33.3%）。中位年龄为66岁,大多数是男性（82%）。从诊断开始整个队列的mOS为6.5个月。然而,接受1L全身治疗的患者的mOS为9.0个月，显着高于其他三个亚组。每位接受HCC治疗的患者的平均费用为49,640加元，口服药物和住院是最大的成本驱动因素。结果强调了在不断发展的治疗选择时代，需要对HCC管理策略进行持续评估和优化。
